To the Editor,

Chronic rhinosinusitis (CRS) is a major public health problem with a high burden on the health system. The studies conducted based on the Global Allergy and Asthma European Network (GA²LEN) reported that the prevalence of CRS in Europe, USA, China and Brazil were 10.9%, 11.9%, 8% and 5.5%, respectively (1-4). For epidemiological studies, the European Position Paper on Rhinosinusitis and Nasal Polyps (EP³OS) defined CRS as an inflammation of the nose and the paranasal sinuses characterized by presence of two or more symptoms, one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); ± facial pain/pressure; ± reduction or loss of smell for more than 12 weeks during the last 12 months (5).

A total of 5201 individuals aged 15-65 years old living in the city of Bushehr, Southwestern Iran were randomly selected through a multistage, stratified, cluster, random sampling method to participate in a population-based survey. We used the standardized GA²LEN questionnaire to identify individuals with CRS based on the above-mentioned criteria and asked the participants if they had ever been told by a doctor that they had chronic sinusitis as self-reported physician-diagnosed CRS. We measured the overall and positive agreements and used kappa statistics to assess the participants if they had ever been told by a doctor that they had chronic sinusitis as self-reported physician-diagnosed CRS. We measured the overall and positive agreements and used kappa statistics to assess the agreement between the two methods of diagnosis of CRS. The overall prevalence of CRS according to the EP³OS-defined criteria and self-reported were 28.4% (95% CI= 27.2%-29.6%) and 20.0% (95%CI: 18.9%-21.1%). There was no significant gender differences between two groups (men: 28.2% vs women: 28.3%, for EP³OS and men: 20.4% vs women: 19.6% for self-reported, p > 0.05). The participants aged 25-34 had the highest prevalence of CRS (Figure 1).

The overall and positive agreement between the two methods were 77.6% and 12.8%, respectively. In addition, Kappa statistics showed a fair agreement between the two methods (Kappa=0.39, p < 0.001).

Among all individuals with the self-reported physician-diagnosed CRS, 36.0% didn’t have CRS based on the EP³OS-defined criteria. Among those who self-reported no history of CRS, 19.0% were diagnosed to have CRS based on EP³OS criteria (Table 1).

Figure 1. Comparison of the prevalence of CRS according to two methods of definition by sex and age group.
SNOT-22 validated for Estonian patients

Table 1. The agreement between diagnoses of chronic rhinosinusitis based on EP3OS criteria and self-reported, physician diagnosed methods.

<table>
<thead>
<tr>
<th>EP3OS</th>
<th>Self-reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
<td>3218 (64.8%)</td>
</tr>
<tr>
<td>Yes</td>
<td>356 (7.2%)</td>
</tr>
</tbody>
</table>

According to the studies conducted based on GA(2)LEN questionnaire, the prevalence of self-reported physician diagnosed CRS in Europe was lower than the prevalence of EP3OS-defined CRS (1). Association was weakest between self-reported physician diagnosed and EP3OS-defined CRS in an American study (2). Moreover, the Chinese study reported that the prevalence of self-reported physician diagnosed CRS (4.3%) was nearly half of the prevalence of EP3OS-defined CRS (8%) (3). While, the prevalence of self-reported physician diagnosed CRS was higher than EP3OS-defined in the city of Sao Paulo, Brazil (4). There are some explanations for the higher CRS prevalence in Bushehr.

In conclusion, the inter-rater agreement between self-reported and EP3OS-based definition of CRS was not high enough to be used interchangeably. However, because the questionnaires were completed by the participants, some of the data was missing for some of the questions.

References

Shokrollah Farrokhi
Department of Immunology and Allergy
the Persian Gulf Tropical Medicine Research Center
Bushehr University of Medical Sciences
Sangi St, Bushehr, Iran
PO Box 75 16 68 88 76
Tel Fax: +98 77 33 32 0361
Mobile: +98 (0) 917-716-7965
E-mail: Farrokhi_Sh@yahoo.com

ISSN: 2589-5613 / ©2019 The Author(s). This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/